Triple Negative Breast Neoplasms
-
Subject Areas on Research
- A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
- Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy.
- Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
- Circulating tumor cell analysis in metastatic triple-negative breast cancers.
- Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.
- Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.
- Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.
- MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
- MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
- MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
- Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis.
- Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
- Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
- Post-irradiation morphoea of the breast: a case report and review of the literature.
- Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
- Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
- The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.
- The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors.
- The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.
- αB-crystallin: a novel regulator of breast cancer metastasis to the brain.